We believe that research on this topic is timely and warranted since a majority of pwCF currently take CFTR modulators, live longer, and maintain persistent microbial colonisations with recurrent infections that may change the microbial landscape of the CF lung. The gene discussed is CFTR; the disease is cystic fibrosis.